t
Between October 7 and 9, 2026, several GSK plc Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) acquired Ordinary Shares and American Depositary Shares (ADS). These acquisitions, made through dividend reinvestment and the Company's Share Reward Plan, occurred at prices ranging from £17.5852 to £17.6650 per Ordinary Share and $47.0200 per ADS on the London Stock Exchange and New York Stock Exchange.
| Date | 12 Oct 2026 |
| Time | 15:30:01 |
| Category | Director/PDMR dealings |
| ID | 6188Y |
GSK plc (the ‘Company’)
Transaction notification
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Luke Miels | |||
|
b) |
Position/status |
Chief Executive Officer | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on shares held through the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.5852 |
3 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-08 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’)
| ||||
|
a) |
Name |
Lynn Baxter | |||
|
b) |
Position/status |
President, Europe | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on shares held through the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.5852 |
39 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-08 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
James Ford | |||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on shares held through the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.5852 |
13 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-08 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
David Redfern | |||
|
b) |
Position/status |
President Corporate Development | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on shares held through the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.5852 |
80 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-08 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Regis Simard | |||
|
b) |
Position/status |
President, Global Supply Chain | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on shares held through the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.5852 |
32 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-08 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Philip Thomson | |||
|
b) |
Position/status |
President, Global Affairs | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on shares held through the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.5852 |
52 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-08 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Deborah Waterhouse | |||
|
b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on shares held through the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.5852 |
66 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-08 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Victoria Whyte | |||
|
b) |
Position/status |
SVP & Company Secretary | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on shares held through the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.5852 |
62 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-08 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Neil Falkingham | |||
|
b) |
Position/status |
PCA of Lynn Baxter (President, Europe) | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
| |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on shares held through the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.5852 |
64
|
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction) | |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-08 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Victoria Whyte | |||
|
b) |
Position/status |
SVP & Company Secretary | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.5904 |
243 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-08 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Iain Whyte | |||
|
b) |
Position/status |
PCA of Victoria Whyte (SVP & Company Secretary) | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.5904 |
1,182 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction) | |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-08 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Maya Martinez-Davis | |||
|
b) |
Position/status |
President, US | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
American Depositary Shares (‘ADS’)
ISIN: US37733W2044 | |||
|
b) |
Nature of the transaction |
Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account
| |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$47.0200 |
10.155 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction) | |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-07 | |||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Lynn Baxter | |||
|
b) |
Position/status |
President, Europe | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
| |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6539 |
7 (partnership shares) |
| ||
|
|
£17.6539 |
7 (matching shares) |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
| |||
|
Aggregated volume Price |
14 Ordinary Shares £17.6539 | ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Julie Brown | |||
|
b) |
Position/status |
Chief Financial Officer | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
| |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6539 |
7 (partnership shares) |
| ||
|
|
£17.6539 |
7 (matching shares) |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
| |||
|
Aggregated volume Price |
14 Ordinary Shares £17.6539 | ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
James Ford | |||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
| |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6539 |
7 (partnership shares) |
| ||
|
|
£17.6539 |
7 (matching shares) |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
| |||
|
Aggregated volume Price |
14 Ordinary Shares £17.6539 | ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
David Redfern | |||
|
b) |
Position/status |
President, Corporate Development | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
| |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6539 |
7 (partnership shares) |
| ||
|
|
£17.6539 |
7 (matching shares) |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
| |||
|
Aggregated volume Price |
14 Ordinary Shares £17.6539 | ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Regis Simard | |||
|
b) |
Position/status |
President, Global Supply Chain | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
| |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6539 |
7 (partnership shares) |
| ||
|
|
£17.6539 |
7 (matching shares) |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
| |||
|
Aggregated volume Price |
14 Ordinary Shares £17.6539 | ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Philip Thomson | |||
|
b) |
Position/status |
President, Global Affairs | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
| |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6539 |
7 (partnership shares) |
| ||
|
|
£17.6539 |
7 (matching shares) |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
| |||
|
Aggregated volume Price |
14 Ordinary Shares £17.6539 | ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Deborah Waterhouse | |||
|
b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
| |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6539 |
7 (partnership shares) |
| ||
|
|
£17.6539 |
7 (matching shares) |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
| |||
|
Aggregated volume Price |
14 Ordinary Shares £17.6539 | ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Victoria Whyte | |||
|
b) |
Position/status |
SVP & Company Secretary | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
| |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6539 |
7 (partnership shares) |
| ||
|
|
£17.6539 |
7 (matching shares) |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
| |||
|
Aggregated volume Price |
14 Ordinary Shares £17.6539 | ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Neil Falkingham | |||
|
b) |
Position/status |
PCA of Lynn Baxter (President, Europe) | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
| |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company’s Share Reward Plan | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6539 |
7 (partnership shares) |
| ||
|
|
£17.6539 |
7 (matching shares) |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
| |||
|
Aggregated volume Price |
14 Ordinary Shares £17.6539 | ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
David Redfern | |||
|
b) |
Position/status |
President Corporate Development | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6650 |
7 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Neil Falkingham | |||
|
b) |
Position/status |
PCA of Lynn Baxter (President, Europe) | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 | |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6650 |
7 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
David Redfern | |||
|
b) |
Position/status |
President Corporate Development | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held within an ISA
| |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6650 |
20 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Victoria Whyte | |||
|
b) |
Position/status |
SVP & Company Secretary | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63 | |||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held within an ISA
| |||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£17.6650 |
17 |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A (single transaction)
| |||
|
Aggregated volume Price |
| ||||
|
e) |
Date of the transaction |
2026-10-09 | |||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) | |||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG